Vitamin D and Cancer Survival: Does Vitamin D Supplementation Improve the Survival of Patients with Cancer?

25-hydroxyvitamin D Meta-analysis Mortality Prognosis Relapse-free survival Vitamin D3

Journal

Current oncology reports
ISSN: 1534-6269
Titre abrégé: Curr Oncol Rep
Pays: United States
ID NLM: 100888967

Informations de publication

Date de publication:
04 06 2020
Historique:
entrez: 5 6 2020
pubmed: 5 6 2020
medline: 24 8 2021
Statut: epublish

Résumé

Clinical evidence suggesting the beneficial effects of vitamin D on survival of patients with cancer has been accumulating. Recent articles were thoroughly reviewed to determine if there is enough evidence to conclude that vitamin D supplementation improves survival of patients with cancer. Meta-analyses of observational studies showed that higher blood 25-hydroxyvitamin D levels in patients with cancer at a variety of sites were associated with lower cancer-specific and overall mortalities. Moreover, meta-analyses of randomized clinical trials (RCTs) also suggested that vitamin D supplementation improved the survival of patients with cancer. However, each RCT used in these meta-analyses, as well as very recent RCTs, e.g., the SUNSHINE and the AMATERASU trial, did not show statistical significance in the primary results. For now, compelling evidence that vitamin D supplementation effectively improves survival of patients with cancer is lacking. Thus, confirmatory RCTs are still obligatory for the future.

Identifiants

pubmed: 32495112
doi: 10.1007/s11912-020-00929-4
pii: 10.1007/s11912-020-00929-4
doi:

Substances chimiques

Vitamin D 1406-16-2
25-hydroxyvitamin D A288AR3C9H

Types de publication

Journal Article Meta-Analysis Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

62

Auteurs

Taisuke Akutsu (T)

Division of Molecular Epidemiology, Jikei University School of Medicine, Nishi-shimbashi 3-25-8, Minato-ku, Tokyo, 105-8461, Japan.

Hikaru Kitamura (H)

Division of Molecular Epidemiology, Jikei University School of Medicine, Nishi-shimbashi 3-25-8, Minato-ku, Tokyo, 105-8461, Japan.

Shoko Himeiwa (S)

Division of Molecular Epidemiology, Jikei University School of Medicine, Nishi-shimbashi 3-25-8, Minato-ku, Tokyo, 105-8461, Japan.

Shinto Kitada (S)

Division of Molecular Epidemiology, Jikei University School of Medicine, Nishi-shimbashi 3-25-8, Minato-ku, Tokyo, 105-8461, Japan.

Tatsuya Akasu (T)

Division of Molecular Epidemiology, Jikei University School of Medicine, Nishi-shimbashi 3-25-8, Minato-ku, Tokyo, 105-8461, Japan.

Mitsuyoshi Urashima (M)

Division of Molecular Epidemiology, Jikei University School of Medicine, Nishi-shimbashi 3-25-8, Minato-ku, Tokyo, 105-8461, Japan. urashima@jikei.ac.jp.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH